BLVRA

Across TCGA pan-cancer cohorts, BLVRA mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of BLVRA’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where BLVRA mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types BLVRA is over-expressed in tumor, although a few such as COAD and LSCC show the opposite, repressed pattern.

CCRCC, COAD, and LSCC are the cancer types where BLVRA tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BLVRA mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	All	+0.457	<.001	12	view →
COAD	Male	III,IV	−0.773	<.001	9	view →
LSCC	Female	II,III,IV	−0.412	<.001	8	view →
PDAC	Female	II,III,IV	+0.302	<.001	7	view →
LUAD	Female	II,III,IV	+0.329	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

BLVRA–CCRCC

Open the CCRCC breakdown →